Ponesimod vs Siponimod (Mayzent)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT02425644 · Phase 3 · completed

This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.

Reported efficacy

Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)

Result source: NCT02425644

Siponimod (Mayzent)

Marketed by Novartis

Approved in Multiple Sclerosissmall molecule
Weak signal

NCT03623243 · Phase 3 · completed

The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.

Reported efficacy

Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) (Baseline, every 3 month up to the maximum of approximately 3 years): EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). (met)

Result source: NCT01665144

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPonesimodSiponimod (Mayzent)
Annualised relapse rate0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644—Trial running · NCT04926818
Free of 3-month confirmed disability progression (%)—Not reported—Trial running · NCT04926818
New or enlarging T2 lesions—Not reported—Trial running · NCT04926818

Annualised relapse rate

Ponesimod
0.2 vs 0.3vs Teriflunomide20 mg · wk 108 · n 567NCT02425644
Siponimod (Mayzent)
—Trial running · NCT04926818

Free of 3-month confirmed disability progression (%)

Ponesimod
—Not reported
Siponimod (Mayzent)
—Trial running · NCT04926818

New or enlarging T2 lesions

Ponesimod
—Not reported
Siponimod (Mayzent)
—Trial running · NCT04926818
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Siponimod (Mayzent)
EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). NCT01665144 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ponesimod: 4 of 4 rows · Siponimod (Mayzent): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPonesimodSiponimod (Mayzent)
Dropout rate
13.6%20 mga
NCT02425644 · Phase 3
show 4 more results
19.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
33.9%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
35%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
38.3%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
21.1%a
NCT03623243 · Phase 3
Discontinued due to AEs
2.3%20 mga
NCT02425644 · Phase 3
show 4 more results
1.6%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
0.8%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
3.4%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
1.7%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
8.1%a
NCT03623243 · Phase 3
Serious AEs
8.7%20 mga
NCT02425644 · Phase 3
show 4 more results
12.8%20 mg
NCT03232073 · Phase 3 · registry result, not featured evidence
24.1%20 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
16.6%40 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
23%10 mg
NCT01093326 · Phase 2 · registry result, not featured evidence
4.9%a
NCT03623243 · Phase 3
Most frequent reported AEs
20 mga
alanine aminotransferase increased 19.5%
nasopharyngitis 19.3%
headache 11.3%
NCT02425644 · Phase 3
show 4 more results
20 mg
covid-19 26.2%
nasopharyngitis 18.7%
alanine aminotransferase increased 16.6%
NCT03232073 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 31.7%
headache 21.4%
upper respiratory tract infection 19.3%
NCT01093326 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 29.8%
headache 27.2%
upper respiratory tract infection 25.8%
NCT01093326 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 33.1%
headache 27.3%
upper respiratory tract infection 19.4%
NCT01093326 · Phase 2 · registry result, not featured evidence
a
headache 13.5%
urinary tract infection 8.6%
nausea 8.1%
NCT03623243 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ponesimod

Annualized Relapse 0.202 vs 0.29 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
FSIQ-RMS Symptoms Domain -0.01 vs 3.56 Teriflunomide score @ 108wk20 mg
absolute change · score
NCT02425644 · Phase 3
CUAL Rate Annualized 1.405 vs 3.164 Teriflunomide per year @ 108wk20 mg
event rate · per year
NCT02425644 · Phase 3
Confirmed Disability Progression 12w 7.6% (n=567) vs 8.3% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
10.8% (n=567) vs 13.2% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Confirmed Disability Progression 24w 6.3% (n=567) vs 6.9% (n=566) Teriflunomide @ 60wk20 mg
responder rate · % of participants
NCT02425644 · Phase 3
show 1 more result
8.7% (n=567) vs 10.5% (n=566) Teriflunomide @ 108wk20 mg
NCT02425644 · Phase 3
Annualized Relapse 0.143 vs 0.184 Teriflunomide then Ponesimod per year20 mg
event rate · per year
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to First Relapse 92.93 vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence · converted to months from 402.71 weeks as posted
Time to 3m Confirmed Disability Worsening NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Time to CDP 6mo NA vs NA Teriflunomide then Ponesimod months20 mg
time to event · months
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
Relapse Free 56.7% (n=439) vs 51.6% (n=438) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
EDSS 0.16 vs 0.34 Teriflunomide then Ponesimod score20 mg
absolute change · score
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence
NEDA 17.5% (n=439) vs 7.5% (n=436) Teriflunomide then Ponesimod20 mg
responder rate · % of participants
Extension (open-label)
NCT03232073 · Phase 3 · registry result, not featured evidence

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · Siponimod (Mayzent)'s landscape